We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Phase II Open-Label Pilot Study of V3381 in Chronic Cough

This study has been terminated.
(Lack of efficacy)
ClinicalTrials.gov Identifier:
First Posted: July 25, 2011
Last Update Posted: July 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Manchester University NHS Foundation Trust
Information provided by:
Vernalis (R&D) Ltd
The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the N-Methyl-D-Aspartate (NMDA) receptor[1-3].

Condition Intervention Phase
Cough Drug: Indantadol Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic

Resource links provided by NLM:

Further study details as provided by Vernalis (R&D) Ltd:

Primary Outcome Measures:
  • Objective cough frequency at 8 weeks compared to baseline. [ Time Frame: 8 Weeks ]

Secondary Outcome Measures:
  • Change in objective cough frequency at 4 weeks. [ Time Frame: 4 Weeks ]
  • Change in Cough-Specific Quality-of-Life Questionnaire (CQLQ) at 4 and 8 weeks. [ Time Frame: 4 and 8 Weeks ]
  • Change in Global Rating of Change Scale at 1 week, 2 weeks, 4 weeks and 8 weeks [ Time Frame: 1 Week, 2 Weeks, 4 Weeks and 8 Weeks ]

Enrollment: 12
Study Start Date: October 2009
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Indantadol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female 18-75 years of age
  • Females must be of non child-bearing potential
  • Chronic Cough ( > 8 weeks)
  • Normal Chest X-ray
  • Normal Lung Function
  • Idiopathic or treatment resistant cough-

Exclusion Criteria:

  • Recent upper respiratory tract infection (<4 weeks)
  • Pregnancy/breast-feeding
  • Current smokers or ex-smokers with <6 months abstinence or cumulative history of >10 pack years
  • Current treatment with ACE inhibitors.
  • Drug or alcohol abuse
  • Uncontrolled hypertension (i.e., >140/90 mmHg despite adequate medical therapy).
  • Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina).
  • Any clinically significant neurological disorder
  • Prior renal transplant, current renal dialysis.
  • Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study.
  • Increased risk of seizures.
  • Any malignancy in the past 2 years (with the exception of basal cell carcinoma).
  • Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).
  • Any clinically significant abnormal laboratory test result(s).
  • Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance <60 mL/min.
  • Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's Syndrome) and/or alanine transaminase (ALT) >1.5 times upper limit of normal reference ranges (after adjustment for age).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01401673

United Kingdom
South Manchester University Hospital
Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
Vernalis (R&D) Ltd
Manchester University NHS Foundation Trust
Principal Investigator: Ashley Woodcock, Prof. South Manchester University Hospital
  More Information

Responsible Party: Development Director, Vernalis (R&D) Ltd
ClinicalTrials.gov Identifier: NCT01401673     History of Changes
Other Study ID Numbers: V001
First Submitted: July 21, 2011
First Posted: July 25, 2011
Last Update Posted: July 25, 2011
Last Verified: July 2011

Keywords provided by Vernalis (R&D) Ltd:
Chronic Cough

Additional relevant MeSH terms:
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms